[{"id":"9bdad34e-56d0-48b9-af40-2c4c90d60427","acronym":"WP42004","url":"https://clinicaltrials.gov/study/NCT04580121","created_at":"2021-06-30T14:53:56.262Z","updated_at":"2024-07-02T16:34:59.484Z","phase":"Phase 1","brief_title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","source_id_and_acronym":"NCT04580121 - WP42004","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 11/04/2020","start_date":" 11/04/2020","primary_txt":" Primary completion: 08/09/2023","primary_completion_date":" 08/09/2023","study_txt":" Completion: 08/09/2023","study_completion_date":" 08/09/2023","last_update_posted":"2024-06-03"}]